scholarly journals The PRE-hospital Stroke Treatment Organization

2017 ◽  
Vol 12 (9) ◽  
pp. 932-940 ◽  
Author(s):  
Heinrich Audebert ◽  
Klaus Fassbender ◽  
M Shazam Hussain ◽  
Martin Ebinger ◽  
Guillaume Turc ◽  
...  
Stroke ◽  
2021 ◽  
Vol 52 (Suppl_1) ◽  
Author(s):  
Kenneth Reichenbach ◽  
Claranne Mathiesen ◽  
Leslie Thomas ◽  
Margaret Hilger ◽  
James C Grotta ◽  
...  

Background: Mobile Stroke Units (MSU) provide hyperacute diagnosis and treatment in the prehospital setting and are growing in number around the world. However, USA MSU reimbursement limits program proliferation and increases dependency on grants to support program costs. Therefore, we aimed to understand the USA MSU reimbursement paradigm. Methods: IRB approval was obtained for the conduct of an anonymous national MSU survey. Survey items were developed by MSU leaders experienced with reimbursement models and disseminated to all USA MSU programs. Returned data were entered and analyzed in SPSS using descriptive statistics. Results: Of the 20 existing USA MSU programs, 19 (95%) returned surveys. Programs work 26 + 6 (median 30) days per month serving a median 240 sq. mile radius with a median 600 dispatches per year; 47% describe their service area as metropolitan, 16% as rural, with 37% serving both. A median 4 people staff the MSU with 37% including an MD and 16% including an APP as the expert on board; the remaining programs use telemedicine MD coverage. Two programs are classified as “virtual ED” with 1 of these not classified as an EMS vehicle; 1 MSU is classified as an “outpatient clinic” with all other programs classified as EMS vehicles; 21% are certified CT Mobile Laboratories. During the last 12 months, overall the 19 responding programs gave on average 72 + 78 (median 30) alteplase tPA treatments. Of the 15 programs providing billing practices, 47% bill EMS ALS charges; supplemental billing included CT (53%), critical care (5%), telemedicine (53%), tPA (21%), and labs (5%), however, collection was poor. Overall, programs described their financial performance as negative, with only 1 program (outpatient clinic) defining it as positive; 100% rely in part or totally on grants, philanthropy, or institutional support to sustain the program. Conclusion: USA billing restrictions challenge MSU financial sustainability limiting reimbursement to traditional EMS ambulance services. Given the importance of early MSU treatment to reduce disability and death, new financial models are needed to ensure the viability of MSU services.


2009 ◽  
Vol 2 (11) ◽  
pp. 9
Author(s):  
AMY ROTHMAN SCHONFELD

2017 ◽  
Vol 14 (6) ◽  
Author(s):  
Xudan Shi ◽  
Liang Xu ◽  
Jay Malagult ◽  
Jiping Tang ◽  
Min Yan ◽  
...  
Keyword(s):  

2018 ◽  
Vol 17 (5) ◽  
pp. 338-347 ◽  
Author(s):  
Shan Wang ◽  
Fei Ma ◽  
Longjian Huang ◽  
Yong Zhang ◽  
Yuchen Peng ◽  
...  

Background and Objective: Stroke is a leading cause of morbidity and mortality in both developed and developing countries all over the world. The only drug for ischemic stroke approved by FDA is recombinant tissue plasminogen activator (rtPA). However, only 2-5% stroke patients receive rtPAs treatment due to its strict therapeutic time window. As ischemic stroke is a complex disease involving multiple mechanisms, medications with multi-targets may be more powerful compared with single-target drugs. Dl-3-n-Butylphthalide (NBP) is a synthetic compound based on l-3-n- Butylphthalide that is isolated from seeds of Apium graveolens. The racemic 3-n-butylphthalide (dl- NBP) was approved by Food and Drug Administration of China for the treatment of ischemic stroke in 2002. A number of clinical studies indicated that NBP not only improved the symptoms of ischemic stroke, but also contributed to the long-term recovery. The potential mechanisms of NBP for ischemic stroke treatment may target different pathophysiological processes, including anti-oxidant, antiinflammation, anti-apoptosis, anti-thrombosis, and protection of mitochondria et al. Conclusion: In this review, we have summarized the research progress of NBP for the treatment of ischemic stroke during the past two decades.


Sign in / Sign up

Export Citation Format

Share Document